Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.

Hadi Zare-Zardini Ashraf AlemiAsghar Taheri-KafraniSeyed Ahmad HosseiniHossein SoltaninejadAmir Ali HamidiehMojtaba Haghi KaramallahMajid FarrokhifarMohammad Farrokhifar

Published in: Drug design, development and therapy (2020)

The enhanced cellular uptake and cytotoxic activity of the Ginsenoside Rh2 nanoniosomal formulation on the PC3 cell make it an attractive candidate for application as a nano-sized delivery vehicle to transfer Ginsenoside Rh2 to cancer cells.

Keyphrases

prostate cancer
drug delivery
single cell
radical prostatectomy
cell therapy
mesenchymal stem cells